StephenHowardEmburyMD

Sickle Cell & Other Anemias

CEO, Vanguard Therapeutics, Inc.

Dr. Embury is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 1972 - 1973
McGaw Medical Center of Northwestern UniversityResidency, Internal Medicine, 1969 - 1970
Northwestern University The Feinberg School of MedicineClass of 1968

PubMed

60 citations
L-Glutamine therapy reduces endothelial adhesion of sickle red blood cells to human umbilical vein endothelial cells
Yutaka Niihara, Neil M. Matsui, Yamin M Shen, Dean A Akiyama, Cage S. Johnson
BMC Blood Disorders. 2005-07-25
1230 citations
Cerebrovascular Accidents in Sickle Cell Disease: Rates and Risk Factors
Kwaku Ohene-Frempong, Steven J. Weiner, Lynn A. Sleeper, Scott T. Miller, Stephen H. Embury
Blood. 1998-01-01
337 citations
The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up
Martin H. Steinberg, William F. McCarthy, Oswaldo Castro, Samir K. Ballas, F. Danny Armstrong
American Journal of Hematology. 2010-06-01

Activated Endothelial Adhesivity In SC VasoocclusionNational Heart, Lung, And Blood Institute2000–2003
Endothelial Cell Reactivity In Sickle Cell VasoocclusionNational Heart, Lung, And Blood Institute1998–2002
Core--Dna Diagnostic Laboratory And West BAY Components--Hemoglobinopathy LABNational Heart, Lung, And Blood Institute1995–1997
Molecular Genetics Of The ThalassemiasNational Heart, Lung, And Blood Institute1985